肺癌
- 肺癌亚型
-
- 小细胞肺癌
- 小细胞肺癌
- 化疗
-
- 拓扑异构酶抑制剂
- Irinotecan
- Etoposide
- Topotecan
- Doxorubicin
- 免疫检查点抑制剂
-
- CTLA-4
- Ipilimumab
- Tremelimumab
- 靶向-KRAS G12C
- Sotorasib
- Adagrasib
- MRTX-1257
- ARS-1620
- Divarasib
- ARS-853
- ASP2453
- Opnurasib
- ADC/PROTAC
-
- c-Met
- Telisotuzumab vedotin
-
- EGFR
- Cetuximab-MMAE
-
- ALK
- MS4078
-
- CEACAM5
- Tusamitamab ravtansine
-
- ROR2
- Ozuriftamab vedotin
- 靶向-HER2
-
- Pan-HER TKIs
- Afatinib
- Neratinib
- Dacomitinib
-
- 选择性HER2 TKIs
- Pyrotinib dimaleate
- Poziotinib
- Sunvozertinib
-
- Anti-HER2单抗
- Trastuzumab
- Pertuzumab
- 靶向-ALK
-
- 一代ALK-TKIs [1]
- Crizotinib
-
- 二代ALK-TKIs [1]
- Ceritinib
- Alectinib
- Brigatinib
- Ensartinib dihydrochloride
-
- 三代ALK-TKIs [1]
- Lorlatinib
- 靶向-EGFR
-
- 二代EGFR-TKIs [2]
- Afatinib
- Dacomitinib
- Neratinib
- Poziotinib
-
- 三代EGFR-TKIs [3] [4]
- Osimertinib
- Mobocertinib
- Rociletinib
- Olmutinib
- Nazartinib
- Alflutinib mesylate
- Almonertinib
- Lazertinib
-
- Anti-EGFR单抗
- Cetuximab
- Panitumumab
- Necitumumab
- 抗血管生成
- Regorafenib
- Axitinib
- Cabozantinib
- Vandetanib
- Bevacizumab
- Ramucirumab
- Apatinib
- Sunitinib
- Nintedanib
- Pazopanib
- Sorafenib
- Cediranib
- 靶向-MET
-
- I型MET-TKIs [5]
- Crizotinib
- Capmatinib
- Tepotinib
- Savolitinib
-
- II型MET-TKIs [5]
- Cabozantinib
- Merestinib
-
- III型MET-TKIs [5]
- Tivantinib
- 靶向-ROS1
-
- 一代ROS1-TKIs [6]
- Crizotinib
-
- 二代ROS1-TKIs [6]
- Ceritinib
- Repotrectinib
-
- 三代ROS1-TKIs [6]
- Lorlatinib
- 靶向-BRAF
-
- 一代(I型)BRAF抑制剂 [7]
- Vemurafenib
- Dabrafenib
- Encorafenib
-
- 二代(I型)BRAF抑制剂 [7]
- AZ 628
- LY3009120
- Belvarafenib
- CCT196969
- Tovorafenib
- Naporafenib
- PLX7904
- Plixorafenib
- 靶向-RET
-
- 选择性RET抑制剂
- Selpercatinib
- Pralsetinib
-
- 非选择性RET抑制剂
- Cabozantinib
- Vandetanib
- Lenvatinib
- Regorafenib
- 相关化合物库
- FDA-approved Anticancer Drug Library
- Anti-cancer Compound Library
- Anti-cancer Compound Library-Ⅱ
- Anti-cancer Metabolism Compound Library
- Cambridge Cancer Compound Library
- FDA-approved Drug Library
参考文献
- [1] Felip E, et al. Annals of Oncology, 2021, 32(5): 620-630.
- [2] Zubair T, et al. Int J Mol Sci. 2023 Jan 31;24(3):2651.
- [3] Singh S, et al. Biochim Biophys Acta Rev Cancer. 2023 Aug 30:188967.
- [4] Chen L, et al. Cancer Invest. 2022 Aug;40(7):590-603.
- [5] Fujino T, et al. J Thorac Oncol. 2019 Oct;14(10):1753-1765.
- [6] Remon J, et al. Cancer Treat Rev. 2021 Apr;95:102178.
- [7] Abdayem P, et al. Clin Adv Hematol Oncol. 2022 Nov;20(11):662-672.
